The FDA ought to change Plan B's label.

Contraception

Department of Communication, Liberal Arts, and Social Sciences, New Mexico Institute of Mining and Technology (New Mexico Tech), Socorro, New Mexico. Electronic address:

Published: February 2022

This commentary defends 3 arguments for changing the label of levonorgestrel-based emergency contraception (LNG EC) so that it no longer supports the possibility of a mechanism of action after fertilization. First, there is no direct scientific evidence confirming any postfertilization mechanisms. Second, despite the weight of evidence, there is still widespread public misunderstanding over the mechanism of LNG EC. Third, this FDA label is not a value-free claim, but instead it has functioned like a political tool for reducing contraceptive access. The label is laden with antiabortion values (even though EC is contraception, not abortion), and it imposes these values on potential users, resulting in barriers to access such as with Burwell v. Hobby Lobby. These 3 arguments together provide scientific, social, and ethical grounds for the FDA to take the initiate in changing Plan B's drug label.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.contraception.2021.10.011DOI Listing

Publication Analysis

Top Keywords

plan b's
8
label
5
fda change
4
change plan
4
b's label
4
label commentary
4
commentary defends
4
defends arguments
4
arguments changing
4
changing label
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!